计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
提供 ≥99% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
2-8°C储存,干燥。低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Infigratinib phosphate (BGJ-398 phosphate; NVP-BGJ398 phosphate) is a potent inhibitor of the FGFR family with IC 50 of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1 , FGFR2 , FGFR3 , and FGFR4 , respectively.
In Vitro
Infigratinib phosphate inhibits FGFR1, FGFR2, and FGFR3 with IC 50 =~1 nM, FGFR3 K650E with IC 50 =4.9 nM, and FGFR4 with IC 50 =60 nM. IC 50 values for all other kinases are in the μM range (FYN, LCK, YES, and ABL, IC 50 =1.9, 2.5, 1.1, and 2.3 μM, respectively) except for VEGFR2, KIT, and LYN, which are inhibited at submicromolar concentrations (IC 50 =0.18, 0.75, and 0.3 μM, respectively). Infigratinib inhibits the proliferation of the FGFR1-, FGFR2-, and FGFR3-dependent BaF3 cells with IC 50 values which are in the low nanomolar range and comparable to those observed for the inhibition of the receptors kinase activity in the enzymatic assay. For the remaining cells, all IC 50 values are greater than 1.5 μM except for VEGFR2 (IC 50 1449 and 938 nM), for which there is at least a 400-fold selectivity versus FGFR1, FGFR2, and FGFR3. Infigratinib (ranging between 1 nM and 10 μM) is potent at inhibiting cell growth of FGFR2 -mutant endometrial cancer cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Infigratinib is administered to athymic nude mice implanted subcutaneously with RT112/luc1 tumors: either as a 5 mg/kg intravenous bolus in NMP/PEG200 (1:9, v/v) or orally by gavage as a suspension in PEG300/D5W (2:1, v/v) at a 20 mg/kg dose. The relevant pharmacokinetic (PK) parameters indicate that the oral bioavailability of Infigratinib in this study is 32%. After intravenous dosing, Infigratinib shows a rapid distribution from the vascular compartment into the peripheral tissues, translating into a high volume of distribution (26 L/kg). The plasma clearance is high at 3.3 L/h/kg (61% of liver blood flow). The ratio of tumor to plasma after oral dosing based on AUC is determined to be 10 . Infigratinib (30 mg/kg) significantly inhibits the growth of FGFR2 -mutated endometrial cancer xenograft models. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Form:Solid
IC50& Target:FGFR1 0.9 nM (IC 50 ) FGFR2 1.4 nM (IC 50 ) FGFR3 1 nM (IC 50 ) FGFR4 60 nM (IC 50 )
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机杂环化合物 |
| 类(Class) | 二嗪烷 |
| 亚类(Subclass) | 哌嗪类 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 苯基哌嗪类 |
| 其他上位类(Alternative Parents) | N-芳基哌嗪 二甲氧基苯 N-苯脲类 甲氧基苯胺 二烷基芳胺 二氯苯 苯氧基化合物 茴香醚 烷基芳基醚 N-烷基哌嗪 氨基嘧啶及其衍生物 咪唑内酰胺类 有机磷酸及其衍生物 芳基氯化物 杂芳族化合物 三烷基胺 尿素 氮杂环化合物 仲胺 羰基化合物 碳氢化合物衍生物 有机氧化物 有机氯化物 |
| 分子骨架(Molecular Framework) | 芳香族杂单环化合物 |
| 取代基(Substituents) | 1,3-二氯苯 - 芳基醚 - 氨基酸 - 氨基吡啶 - 苯胺或取代苯胺 - 茴香醚 - 芳香族杂单环化合物 - 芳基氯化物 - 芳基卤化物 - 氮杂环 - 苯基化合物 - 羰基 - 氯苯 - 二烷基芳基胺 - 二甲氧基苯 - 乙醚 - 卤苯 - 杂芳香族化合物 - 烃衍生物 - 咪唑内酰胺 - 邻二甲氧基苯 - 甲氧基苯胺 - 甲氧基苯 - 单环苯基基团 - N-烷基哌嗪 - N-芳基哌嗪 - N-吡咯烷酮 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机磷酸酯 - 有机氯化物 - 有机卤化物 - 有机氮化合物 - 有机氧化合物 - 苯酚醚 - 苯氧基化合物 - 苯基哌嗪 - 嘧啶 - 醛基 - 三元脂肪胺 - 三芳基胺 - 脲 |
| 描述(Description) | 该化合物属于苯基哌嗪类有机化合物。这类化合物具有苯基哌嗪骨架,即哌嗪环与苯基相连的结构。 |
| 外部描述符(External Descriptors) | 暂无 |
| 活性类型 | Relation | Activity value | Units | Action Type | 期刊 | PubMed Id | doi | Assay Aladdin ID |
|---|
| 活性类型 | Relation | Activity value | Units | Action Type | 期刊 | PubMed Id | doi | Assay Aladdin ID |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|